Price Alert

Protagonist Therapeutics ... (PTGX)

NASDAQ: PTGX · Real-Time Price · USD

60.53

0.93 (1.56%)

At close: Sep 05, 2025, 3:59 PM

60.73

0.33%

After-hours: Sep 05, 2025, 06:32 PM EDT

1.56% (1D)

Bid	58.2
Market Cap	3.77B
Revenue (ttm)	203.63M
Net Income (ttm)	52.04M
EPS (ttm)	0.73
PE Ratio (ttm)	82.92
Forward PE	-528.27
Analyst	Buy

Ask	61.15
Volume	1,860,381
Avg. Volume (20D)	798,312
Open	58.87
Previous Close	59.60
Day's Range	58.03 - 61.06
52-Week Range	33.31 - 61.89
Beta	2.33

About PTGX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PTGX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Protagonist Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+45.89%

Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription

6 months ago

+2.42%

Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.

News

3 days ago · seekingalpha.com

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conferen...

1 week ago · accessnewswire.com

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

4 weeks ago · fool.com

Protagonist (PTGX) Q2 Revenue Falls 26%

1 month ago · zacks.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.

1 month ago · accessnewswire.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of ico...

2 months ago · accessnewswire.com

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the...

2 months ago · seekingalpha.com

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...